Summary - A new market study, titled “COVID-19 Impact on Global Anti-counterfeit Pharmaceuticals and Cosmetics, Market Insights and Forecast to 2026 ” has been featured on WiseGuyReports.Anti-counterfeit Pharmaceuticals and Cosmetics market is segmented by Type, and by Application.Players, stakeholders, and other participants in the global Anti-counterfeit Pharmaceuticals and Cosmetics market will be able to gain the upper hand as they use the report as a powerful resource.The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026ALSO READ: https://www.einpresswire.com/article/522288185/global-anti-counterfeit-pharmaceuticals-and-cosmetics-market-2020-share-trend-segmentation-and-forecast-to-2026Segment by Type, the Anti-counterfeit Pharmaceuticals and Cosmetics market is segmented into Anti-counterfeit Pharmaceutical Anti-counterfeit CosmeticsSegment by Application, the Anti-counterfeit Pharmaceuticals and Cosmetics market is segmented into Pharma & Healthcare Cosmetics OthersRegional and Country-level Analysis The Anti-counterfeit Pharmaceuticals and Cosmetics market is analysed and market size information is provided by regions (countries).It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.Competitive Landscape and Anti-counterfeit Pharmaceuticals and Cosmetics Market Share Analysis Anti-counterfeit Pharmaceuticals and Cosmetics market competitive landscape provides details and data information by players.
We supply pharmaceutical products well medicated and top quality products and our shipping system is well secured and fast.https://nociw54456.wixsite.com/mysite/post/regarding-pharmaceutical-products-1
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.The major players in the ellagic acid market include Kanwinn Pharmchem, Nektium Pharma, Staherb, Sabinsa, Spec Chem, Shanxi NHK Technology, Plamed Green Science Group, Wuhan Vanz Pharm, Xi& Lyphar Biotech, Xa Bc-Biotech, Baoji Runyu Technology, Herblink Biotech.This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global Ellagic Acid Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/ellagic-acid-market/download-sampleMarket DynamicsThe rising prevalence of cancer cases and obesity worldwide is the primary factor driving the ellagic acid market over the forecast time frame.In addition to that, growing skincare benefits of ellagic acid such as anti-inflammatory, antioxidant, reduces hyperpigmentation, brightening agent, etc.Moreover, ellagic acid medicinal properties have prompted research, and growing awareness among people regarding antioxidants is likely to provide profitable growth opportunities for key players in the coming years.The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis.
Tissue Engineering Market: Information by Material (Nano-fibrous Material, Biomimetic Material, Composite Material and Nano-composite Material) by Application (Orthopedics, Musculoskeletal and Spine, Skin/Integumentary, Cancer, Dental, Cardiology, Urology, Neurology, Cord Blood & Cell Banking and GI & Gynecology) and Region – Forecast till 2024Global Tissue Engineering Market is growing continually, witnessing a rising demand for the process.The market is predominantly driven by the rising popularity of the process in sectors ranging from musculoskeletal & spine, orthopedics, dental, and skin/integumentary to cancer, neurology, and cardiology treatments.Moreover, widening application areas of the tissue engineering process in stem cell reconstructive, skin grafting, and regenerative medicine to treat myriads of chronic diseases escalate the market growth to furthered height.According to Market Research Future (MRFR), the global tissue engineering market is poised to touch a valuation of USD 53,424.00 MN by 2024, growing steadily at 17.84% CAGR throughout the forecast period (2019 – 2024).Also, increasing prevalence of road accidents, injuries, and trauma cases drive the market substantially, driving the demand for transplants and surgical reconstruction procedures.Furthermore, the funding support for the ongoing tissue regeneration researches is a major growth driver supporting the market.Market drivers and restraints:Drivers:Increased focus of pharma & biotechnology companies on the development of tissue engineering-based therapies.Emergence of 3D bio-printing technology as a novel, cost effective tissue engineering strategy.Social media platforms and celebrity endorsements that are spreading the awareness of tissue engineering.Restraints:Lack of awareness of the benefits of tissue engineering.Lack of skilled professionals.Stringent regulatory policies.Global Tissue Engineering Market – SegmentsThe analysis has been segmented into three main dynamics to widen the scope of understanding,By Material : Nano-Fibrous & Biomimetic Materials, Composite & Nano-Composite Materials, and others.By Application : Musculoskeletal & Spine, Orthopedics, Cancer, Dental, Skin/Integumentary, Cardiology, Neurology, Urology, Cord Blood & Cell Banking, GI & Gynecology, and others.By Regions : Americas, Europe, Asia-Pacific, Middle East & Africa, and Rest-of-the-World.Request For Free Sample Copy :https://www.marketresearchfuture.com/sample_request/2134Tissue Engineering Market – Regional AnalysisNorth America dominates the global tissue engineering market.Moreover, factors such as the rising prevalence of chronic diseases, the increasing clinical trials to evaluate the therapeutic potential of products, and well-spread awareness towards the therapeutic potency of therapy foster the regional market growth.
Futuristic Research has recently published a research report titled, “Global Morphine Market Report, History and Forecast 2020-2027, Breakdown Data by Manufacturers, Key Regions, Types and Application“.This report has been prepared by experienced and knowledgeable market experts and researchers.It is an extraordinary accumulation of significant studies that explore the competitive landscape, segmentation, geographical expansion, and revenue, production, and utilization improvement of the global Morphine market.Players can utilize the exact market facts and figures and statistical studies provided in the report to understand the current and future growth of the global Morphine market.The report conveys significant experiences on market revenue, SWOT Analysis, market share, profit estimation and regional landscape of this business vertical.Moreover, the report focuses on significant development components and obstacles accepted by market leaders in the Morphine market.The report depicts information with respect to the current renumeration, current market elements , industry share, cyclic deliverables, market size, and profits anticipation for the analysis timeframe.Detailed TOC along with also Charts & Tables of Morphine Market Research Report accessible at: https://www.futuristicresearch.com/request-sample/FR100124Key Players Mentioned at the Morphine Market Report:Alcaliber SAPfizer Inc.Mallinckrodt LLCPurdue Pharma L.PMacfarlan Smith LtdVerve Health Care Ltd.Sanofi Winthrop Industries A.Sun Pharmaceutical Industries Ltd.Qinghai Pharmaceutical Co. Ltd.Johnson Matthey Fine ChemicalsNortheast Pharmaceutical Group Co. Ltd.This Morphine report analysis attainability with a goal of instructive new players concerning the progressions within the market.
The Global Human Vaccine Adjuvants market report study the current landscape and important projections for market forecast, growth trend.The intended audience also includes Human Vaccine Adjuvants CEOs, provider groups, payer groups and investment firms working in the sector.Market Overview:This Report covers the manufacturers data, including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better.This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.the researchers have used SWOT analysis to study the various strengths, weaknesses, opportunities, and trends the manufacturers are using to expand their share.Competitive LandscapeThe Global Human Vaccine Adjuvants Market study report will provide a valuable insight with an emphasis on global market including some of the major players such as GSK, CSL Limited, Brenntag Biosector, SEPPIC, SPI Pharma, Novavax, Avanti Polar Lipids, Aphios.The competitive landscape section also includes key development strategies, market share and market ranking analysis of the above mentioned players globally.Regions and Countries Level Analysis:Regional analysis is another highly comprehensive part of the research and analysis study of the global Human Vaccine Adjuvants market presented in the report.For the historical and forecast period 2015 to 2026, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Human Vaccine Adjuvants market.The report offers in-depth assessment of the growth and other aspects of the Human Vaccine Adjuvants market in important countries (regions), including:The Middle East and Africa (GCC Countries and Egypt)North America (the United States, Mexico, and Canada)South America (Brazil etc.
 To order this 330+ page report, please visit this link Key InclusionsA detailed assessment of the current market landscape of targeted protein degradation-based therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, company size and location of headquarters), clinical study sponsor(s) and collaborator(s), type of protein degrader (degronimids, ENDTACs, epichaperome inhibitors, hydrophobic tags, IMiDs, LYTACs, molecular glues, PHOTACs, PROTACs, protein homeostatic modulators, SARDs, SERDs, SNIPERs, and specific BET and DUB inhibitors), phase of development (clinical, preclinical, and discovery stage) of product candidates, target indication(s), key therapeutic area(s), type of target protein(s), target enzyme(s) (if available), target signaling pathway (if available), mechanism of action (if available), type of therapy (monotherapy and combination therapy), route of administration (oral, intravenous and others), and information on special drug designations (if any).In addition, the chapter highlights the various technology platforms that are being actively used for the development of targeted protein degraders.Elaborate profiles of key players that are engaged in the development of targeted protein degraders (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed descriptions of their respective lead drug candidates, and an informed future outlook.Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and a brief summary of its developmental history.Brief tabulated profiles of industry players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as year of establishment, location of headquarters, number of employees, and key members of the executive team), recent developments, along with descriptions of their respective drug candidates.A detailed clinical trial analysis of completed, ongoing and planned studies of various targeted protein degraders, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, enrolled patient population and regional distribution of trials, type of protein degrader, phase of development, study design, leading industry and non-industry players (in terms of number of trials conducted), study focus, target therapeutic area, key indications, and clinical endpoints.An assessment of the relative experience of key opinion leaders (KOLs) within this domain, (shortlisted based on their involvement in various clinical studies), featuring detailed 2X2 matrices (based on the strength and activeness of KOLs), a schematic world map representation (highlighting the geographical locations of eminent scientists / researchers) and an analysis evaluating the (relative) level of expertise of different KOLs, based on parameters such as number of publications, number of citations, participation in clinical trials, number of affiliations and strength of professional network (based on information available on ResearchGate).A detailed publication analysis of more than 210 peer-reviewed, scientific articles that have been published since 2017, highlighting the research focus within the industry.It also highlights the key trends observed across the publications, including information on novel protein degraders, potential target proteins, target disease indications, and analysis based on various relevant parameters, such as year of publication, and most popular journals (in terms of number of articles published in the given time period) within this domain.An analysis of the partnerships that have been established in the domain, over the period 2014-Q3 2019, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Type of payment of licensing agreementsUpfront paymentsMilestone payments Type of protein degraderDegronimidsPROTACsSARDs / SERDsSpecific BET and DUB inhibitorsOther protein degraders Therapeutic areaNeurodegenerative disordersOncological disordersOther therapeutic areas Route of administrationOralIntravenousOther routes Key geographical regionNorth AmericaEuropeAsia-Pacific To request a sample pages, please visit this link Key Questions AnsweredWhat are the prevalent R trends related to targeted protein degradation?Which clinical conditions can be treated using targeted protein degradation-based therapeutics?What are the most popular proteins being targeted by bifunctional degrader molecules?What are the key challenges faced by stakeholders engaged in this domain?What are the key technology platforms that leverage the concept of targeted protein degradation?Who are the leading industry and non-industry players in this market?What are the contributions of big pharma players in this field?What are the key geographies where research on targeted protein degradation is being conducted?Who are the key investors in this domain?Who are the key opinion leaders / experts in this field?What kind of partnership models are commonly adopted by industry stakeholders?What are the factors that are likely to influence the evolution of this upcoming market?How is the current and future market opportunity likely to be distributed across key market segments?You may also be interested in the following titles:DNA-Encoded Libraries: Platforms and Services MarketGlobal Stem Cells Market: Focus on Clinical Therapies, 2020–2030The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030  Contact Details:Gaurav Chaudhary+1 (415) 800 [email protected] 
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare.The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago.Presently, a variety of other such chemical entities and molecular glues are under investigation.In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:Type of payment of licensing agreementsUpfront paymentsMilestone payments Type of protein degraderDegronimidsPROTACsSARDs / SERDsSpecific BET and DUB inhibitorsOther protein degraders Therapeutic areaNeurodegenerative disordersOncological disordersOther therapeutic areas Route of administrationOralIntravenousOther routes Key geographical regionNorth AmericaEuropeAsia-Pacific The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:ArvinasCaptor TherapeuticsCelgeneGenetechKymera TherapeuticsMission TherapeuticsProgenraRadius HealthSanofi GenzymeZenopharm Table of Contents  Preface Executive Summary Introduction Current Market Landscape Company Profiles Clinical Trial Analysis KOL Analysis Publication Analysis Funding and Investment Analysis Partnerships and Collaborations Market Sizing and Opportunity Analysis Executive Insights  Concluding Remarks  Appendix 1: Tabulated Data  Appendix 2: List of Companies and Organizations To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Contact DetailsGaurav Chaudhary+1 (415) 800 [email protected]  
Roots Analysis has done a detailed study on Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link Key Market InsightsMore than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are 25+ technology platforms available for use in therapy development effortsThe pipeline features a variety of candidate drugs that target a wide range of disease-causing / associated proteins; majority of the existing drug candidates are designed for administration via non-invasive routesAlthough start-ups and mid-sized firms are spearheading the innovation, several big pharmaceutical companies are also engaged in this domainClose to 5,500 patients were estimated to have been enrolled in clinical trials worldwide, evaluating a number of relevant pre-marketing end points across various phases of developmentA number of prominent scientists from renowned universities have emerged as key opinion leaders, owing to their active involvement in clinical development effortsPublished scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on PROTACsForeseeing a lucrative future, several private and public investors have invested over USD 3.5 billion across close to 100 instances of funding since 2014The increasing interest in this field is also reflected in recent partnership activity; most of these deals are focused on novel technology platforms, involving the active participation of both international and indigenous companiesShort term opportunity in this market is likely to be driven by licensing activity, depending on the capability of novel technologies to meet protein degrader design and development needsAs multiple mid-late stage drug candidates are approved for marketing, the long term opportunity is likely to be distributed across different types of protein degraders, target therapeutic areas and various global regions For more information please visit:https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html Table of Contents  PREFACE1.1.Selective Hormone Receptor Degraders (SHRDs)3.8.2.Targeted Protein Degradation-based Therapeutics and Technologies: Development Pipeline4.2.1.KOL Profile (Edward O’Mara)  PUBLICATION ANALYSIS8.1.Targeted Protein Degradation-based Therapeutics and Technologies Market for Neurodegenerative Disorders, 2020-203011.3.4.2.
To order this 750+ page report, please visit this link Key InclusionsA detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics.Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.In addition, it provides information on the technology advancements related to biomanufacturing.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research.The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-Pacific To request sample pages, please visit this link Key Questions AnsweredWho are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?What is the global demand for biologics-based therapies?What are the major recent developments (such as partnerships and expansions) in this industry?What kind of partnership models are commonly adopted by stakeholders in this domain?What is the current, installed contract manufacturing capacity for biologics?How is the current and future market opportunity likely to be distributed across key market segments?
 Owing to the ever-increasing number of start-ups that are involved in R of novel biologics, there is an enormous opportunity for the CMOs in this domain.It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific manufacturing requirements.The contemporary contract services market features a mix of large and small-sized CMOs and is characterized by multiple mergers and acquisitions as stakeholders strive to broaden their respective service portfolios.This has enabled several CMOs to offer end-to-end services, ranging from drug development, including preliminary R, preclinical and clinical trials, to commercial scale production and regulatory filings To order this 750+ page report, which features 200+ figures and 250+ tables, please visit this link The USD 13.9 billion (by 2030) financial opportunity within the biopharmaceutical manufacturing market has been analyzed across the following segments:Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World  The Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030. report features the following companies, which we identified to be key players in this domain: 3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International  Table of Contents  Preface 2.Executive Summary Introduction Competitive Landscape Biopharmaceutical Contract Manufacturing in North America Biopharmaceutical Contract Manufacturing in Europe Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World Biopharmaceutical Contract Manufacturing in Asia Pacific And the Rest of The World Case Study: Outsourcing of Biosimilars Case Study: Comparison of Small Molecule and Large Molecule Drugs / Therapies  Case Study on In-House Manufacturing Collaborations Recent Developments Capacity Analysis  Demand Analysis  Market Forecast  SWOT Analysis  Future of The Biopharmaceutical CMO Market  Survey Analysis  Interview Transcripts  Appendix 1: List of Non-Industry Players  Appendix 1: List of Non-Industry Players  Appendix 3: List of Companies and Organizations To purchase a copy, please visit https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Contact Details Gaurav Chaudhary+1 (415) 800 [email protected]    
Outsourcing has become a popular trend among biopharmaceutical developers, allowing them to leverage the expertise / larger production capacities of CMOs / CDMOs and achieve significant cost and time related advantages Roots Analysis is pleased to announce the publication of its recent study, titled,  “Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030.”  The report features an extensive study on the contract service providers within the biopharmaceutical industry.The study features in-depth analysis, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and CDMOs.Amongst other elements, the report includes:A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters.Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing, and packaging of biologics.A detailed discussion on the key enablers in this domain, including certain niche product classes, which are likely to have a significant impact on the growth of the contract services market.A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics.A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity.An in-depth analysis of more than 490 grants that have been awarded to research institutes engaged in next generation immune checkpoint therapy-related projects.An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders.A discussion on affiliated trends, key drivers, and challenges, under a comprehensive SWOT framework.A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)Commonly Outsourced Business OperationsActive Pharmaceutical Ingredients (API)Finished Dosage Formulations (FDF)Types of Expression SystemMammalianMicrobialOthersCompany SizeSmallMid-SizedLarge and Very LargeScale of OperationPreclinicalClinicalCommercialKey Geographical Region North AmericaEuropeAsia-PacificRest of the World  The report also features detailed transcripts of discussions held with the following experts:Astrid Brammer, Senior Manager Business Development, Richter-Helm Mathias Schmidt (Chief Executive Officer, ArmaGen)Birgit Schwab, Senior Manager Strategic Marketing, Rentschler BiotechnologieChristian Bailly, Director of CDMO, Pierre FabreClaire Otjes, Assistant Marketing Manager, Batavia BiosciencesDavid C Cunningham, Director Corporate Development, Goodwin BiotechnologyDietmar Katinger, Chief Executive Officer, Polymun ScientificDenis Angioletti, Chief Commercial Officer, Cerbios-PharmaJeffrey Hung, Chief Commercial Officer, Vigene BiosciencesKevin Daley, Director Pharmaceuticals, NovasepMark Wright, Site Head, Grangemouth, Piramal HealthcareNicolas Grandchamp, R Leader, GEG TechRaquel Fortunato, Chief Executive Officer, GenIbet BiopharmaceuticalsSebastian Schuck, Head of Business Development, Wacker BiotechStephen Taylor, Senior Vice President Commercial, FUJIFILM Diosynth BiotechnologiesTatjana Buchholz, Marketing Manager, PlasmidFactory and Marco Schmeer, Project Manager, PlasmidFactoryTim Oldham, Chief Executive Officer, Cell Therapies Key companies covered in the report3P BiopharmaceuticalsAbzenaAlbany Molecular ResearchBioVectraBioXcellence (Boehringer Ingelheim)CelonicCharles River LaboratoriesChemPartnerCobra BiologicsCordenPharmaCytovance BiologicsGE HealthcareGoodwin BiotechnologyGrand River Aseptic ManufacturingIDT BiologikaKBI BioPharmaKemwell BiopharmaLFB BiomanufacturingMeridian Life SciencePatheonPfizer CentreOnePX'TherapeuticsSamsung BioLogicsSanofi, CEPiAThermo Fisher ScientificVetter Pharma International For more information please click on the following link:Biopharma Contract Manufacturing Market (3rd Edition), 2019-2030 Other Recent OfferingsCell Therapy Manufacturing Market (3rd Edition), 2019-2030Antibody Contract Manufacturing Market, 2020-2030China Biopharmaceutical Contract Manufacturing Market, 2020-2030Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots AnalysisRoots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry.The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector.If you’d like help with your growing business needs, get in touch at [email protected] Contact InformationRoots Analysis Private LimitedGaurav Chaudhary+1 (415) 800 [email protected]  
Summary -   A new market study, titled “Global Pharma Regulatory Management Systems Market Size, Status and Forecast 2020-2026” has been featured on Wise Guy Reports.This report focuses on the global Pharma Regulatory Management Systems status, future forecast, growth opportunity, key market and key players.The study objectives are to present the Pharma Regulatory Management Systems development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.ALSO READ: https://www.wfmj.com/our-apologies The key players covered in this studyInstem (Samarind)NNITEXTEDOAmplexorMasterControl... Market segment by Type, the product can be split intoSoftwareServiceMarket segment by Application, split intoPharmaceuticalsBiotechnologyOthers Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America The study objectives of this report are:To analyze global Pharma Regulatory Management Systems status, future forecast, growth opportunity, key market and key players.To present the Pharma Regulatory Management Systems development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.In this study, the years considered to estimate the market size of Pharma Regulatory Management Systems are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year.Whenever data information was unavailable for the base year, the prior year has been considered.FOR MORE DETAILS: https://www.wiseguyreports.com/reports/4896616-global-pharma-regulatory-management-systems-market-size-status  About Us :Wise Guy Reports is part of the Wise Guy Research Consultants Pvt.
Summary - A new market study, titled “Covid-19 Impact on Medical Washer-disinfectors Market, Global Research Reports 2020-2021 ” has been featured on WiseGuyReports.This report covers market size and forecasts of Medical Washer-disinfectors, including the following market information: Global Medical Washer-disinfectors Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global Medical Washer-disinfectors Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global Medical Washer-disinfectors Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K Units) Global Medical Washer-disinfectors Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K Units)ALSO READ: https://industrytoday.co.uk/health_and_safety/global-medical-washer-disinfectors-market-2020-trends--market-share--industry-size--growth--sales--opportunities--analysis-and-forecast-to-2026Key market players Major competitors identified in this market include AT-OS, Belimed, Choyang Medical, DGM Pharma-Apparate Handel, ERYIGIT Medical Devices, Matachana, MedisafeInternational, Miele & Cie. KG, Shinva Medical Instrument, SMEG, Steelco, STERIS, Tuttnauer, etc.Based on the Region: Asia-Pacific (China, Japan, South Korea, India and ASEAN) North America (US and Canada) Europe (Germany, France, UK and Italy) Rest of World (Latin America, Middle East & Africa)Based on the Type: Floor-standing Bench-top OthersBased on the Application: Medical Dental LaboratoryFOR MORE DETAILS:  https://www.wiseguyreports.com/reports/5328359-covid-19-impact-on-medical-washer-disinfectors-marketAbout Us:Wise Guy Reports is part of the Wise Guy Research Consultants Pvt.Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.Contact Us:NORAH TRENT                                                      [email protected]       Ph: +162-825-80070 (US)                          Ph: +44 203 500 2763 (UK
Summary - A new market study, titled “Global CBD Hemp Oil Market Growth 2020-2025” has been featured on WiseGuyReports.According to this study, over the next five years the CBD Hemp Oil market will register a 29.4%% CAGR in terms of revenue, the global market size will reach $ 697.7 million by 2025, from $ 249.2 million in 2019.In particular, this report presents the global market share (sales and revenue) of key companies in CBD Hemp Oil business, shared in Chapter 3.This report presents a comprehensive overview, market shares, and growth opportunities of CBD Hemp Oil market by product type, application, key manufacturers and key regions and countries.This study specially analyses the impact of Covid-19 outbreak on the CBD Hemp Oil, covering the supply chain analysis, impact assessment to the CBD Hemp Oil market size growth rate in several scenarios, and the measures to be undertaken by CBD Hemp Oil companies in response to the COVID-19 epidemic.Also Read: https://www.newsmaker.com.au/news/379036/cbd-hemp-oil-market-2020-global-industry-analysis-by-key-players-segmentation-trends-and-forecast-by-2026#.X2IA2mgzbIUSegmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.Food GradePharmaceutical Grade Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.CBD NutraceuticalCBD FoodCBD CosmeticsCBD MedicalOthers This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.AmericasUnited StatesCanadaMexicoBrazilAPACChinaJapanKoreaSoutheast AsiaIndiaAustraliaEuropeGermanyFranceUKItalyRussiaMiddle East & AfricaEgyptSouth AfricaIsraelTurkeyGCC Countries The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market.The key manufacturers covered in this report: Breakdown data in in Chapter 3.CannavestMH medical hemp GmbHPharmahempBAFA GmbhProtect Pharma RakitovicaENDOCAHarmonyBiobloom HempDragonflyCBDDeep Nature ProjectCeltic WindOpencrop GmbHHemPolandElixinol In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole.
Summary - A new market study, titled Global Cancer Vaccines Market Insights and Forecast to 2026” has been featured on WiseGuyReports.Cancer Vaccines market is segmented by Type, and by Application.The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.Segment by Type, the Cancer Vaccines market is segmented intoPreventive Cancer VaccinesTherapeutic Cancer Vaccines Segment by Application, the Cancer Vaccines market is segmented intoCervical CancerProstate CancerOthersAlso Read: http://www.marketwatch.com/story/global-cancer-vaccines-market-analysis-2020-dynamics-trends-revenue-regional-segmented-outlook-forecast-till-2026-2020-08-24Regional and Country-level AnalysisThe Cancer Vaccines market is analysed and market size information is provided by regions (countries).The key regions covered in the Cancer Vaccines market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa.It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026.It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.Competitive Landscape and Cancer Vaccines Market Share AnalysisCancer Vaccines market competitive landscape provides details and data information by players.The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020.
Summary- A new market study, titled “Global Prostate Cancer Market Insights & Forecast with Potential Impact of COVID-19 2020-2024 “Market OverviewThe global prostate cancer market is anticipated to reach US$14.41 billion in 2024, witnessing growth at a CAGR of 4.62%, over the period 2020-2024.A few notable trends may include expansion of pharmaceutical industry, growing burden of prostate cancer and advancements in oncology.The global prostate cancer market can be categorized on the basis of cancer type, drug and therapy.According to drugs, the global prostate cancer market can be split into Enzalutamide, Abiraterone Acetate, Leuprorelin and other drugs.Whereas, in terms of therapy, the global prostate cancer market can be bifurcated into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and other therapies.The fastest growing regional market is North America due to rising prevalence of prostate cancer in the region, highly competitive and developed medical sector, high investment in research and development activities for the development of newer immunotherapies and targeted drug therapies to treat various cancers.
 The Global Aqua Feed Supplement Market Report 2020-2026 provides in-depth information on the qualitative and quantitative evaluation of the Global Cosmetic Surgery Market.Our analysis on Company Profiling of key market players gives an idea about the supply chain in the marketplace for the year 2020, and also their financial performance gives an idea about market share.Each sub-segment analysis helps to explore new opportunities and areas for improvement.For Right Perspective & Competitive Insights, Request a Sample @: https://introspectivemarketresearch.com/request/13710Key Player Mentioned: Anfotal Nutritions, Roshan Pharmaceuticals, Aspartika Biotech, Citrus Biotek, Bentoli, NS International, CRYSTAL PHARMA, Cifal Herbal Private Ltd, RAINBOW HEALTH CARE PRODUCTS, Hind Trading Co, Biogold Industries LLP, Pasura Crop Care Pvt.Currently, the US accounts for the highest market share of the global Aqua Feed Supplement market, and it is expected to increase in the coming years further.It also offers major insights over the profits of these companies in the particular segments and regions along with the cost trends of the goods in the different markets.In addition, the investigation of market events and their impacts on the international and regional sales of goods are mentioned in the Aqua Feed Supplement market report.The report clearly shows that the Aqua Feed Supplement industry has grown significantly since 2020, based on an in-depth assessment of this industry.
Summary -   A new market study, titled “COVID-19 Impact on Global Food Allergy Diagnostics and Therapeutics Market Size, Status and Forecast 2020-2026” has been featured on Wise Guy Reports.This report focuses on the global Food Allergy Diagnostics and Therapeutics status, future forecast, growth opportunity, key market and key players.The study objectives are to present the Food Allergy Diagnostics and Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.ALSO READ: https://www.medgadget.com/2020/08/food-allergy-diagnostics-and-therapeutics-market-2020-global-leading-companies-analysis-revenue-trends-and-forecasts-2026.html The key players covered in this studyAllergy TherapeuticsCambridge Allergy LtdAstellas Pharma, Inc.Immunomic Therapeutics, Inc.Prota Therapeutics Pty LtdAimmune TherapeuticsPfizerALK-Abello LtdMedeca Pharma ABBioMerieuxOmega Diagnostics GroupHYCOR BiomedicalHOB Biotech Group Market segment by Type, the product can be split intoDiagnostic ProductsInstrumentsConsumablesServicesMarket segment by Application, split intoAcademic Research InstitutesHospitals & ClinicsDiagnostics Laboratories Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America The study objectives of this report are:To analyze global Food Allergy Diagnostics and Therapeutics status, future forecast, growth opportunity, key market and key players.To present the Food Allergy Diagnostics and Therapeutics development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.In this study, the years considered to estimate the market size of Food Allergy Diagnostics and Therapeutics are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year.Whenever data information was unavailable for the base year, the prior year has been considered.FOR MORE DETAILS: https://www.wiseguyreports.com/reports/5497928-covid-19-impact-on-global-food-allergy-diagnostics  About Us :Wise Guy Reports is part of the Wise Guy Research Consultants Pvt.
Reports and Data has added a new informative research report titled Global Fertility Testing Devices Market report to its ever-expanding database, which provides an in-depth assessment of the challenges and growth prospects faced by the Fertility Testing Devices industry currently and a futuristic outlook for the same.The report aims to help the participants, companies, and readers understand the market scenario thoroughly, along with the problems or hurdles they might potentially face over the coming years.Furthermore, the report strives to offer an accurate analysis of the market pertaining to the impact of the COVID-19 pandemic on the Fertility Testing Devices industry and its key verticals.The COVID-19 crisis has dynamically altered the economic scenario of the world and given rise to certain disruptions in the operations of the Fertility Testing Devices market on the global as well as regional level.The report is updated with the latest impact of the COVID-19 pandemic, current and future outlook of the economic scenario, along with a present and future impact of the COVID-19 pandemic on the overall Fertility Testing Devices market.Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/2510The research report delivers a comprehensive assessment of the existing and projected market scenario to offer estimations of the anticipated growth rate of the industry vertical over the forecast period of 2020-2027.Moreover, the report also offers key solutions and methodologies to help the companies and readers overcome the impact of the COVID-19 pandemic on the market.The market is further segmented into product types offered in the market and their application spectrum along with key geographical regions where the market has established substantial footing and comprehensive competitive analysis.The key companies profiled in the report include:Advacare Pharma (U.S.), AVA, Babystart (UK), Fertility Focus (UK), Geratherm Medical (Germany), Hilin Life Products (U.S.), Sensiia (UK), Taidoc, Medical Uebe (Germany), Valley Electronics (Switzerland) Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/2510Product Outlook (Revenue in Million USD; 2016–2026)Ovulation test kitsSaliva & Strip BasedMonitor Touch ScreenFertility monitorsUrine-Based MonitorsPregnancy Rapid TestLine IndicatorsStrip/Dip SticksMid-Stream DeviceCassettesOther Fertility MonitorsBasal Body Temperature,Cervical Mucus,Perspiration MonitoringMale Fertility Testing ProductMode of Purchase Outlook (Revenue in Million USD; 2016–2026)OTC & Non PrescriptionPrescription basedType Outlook (Revenue in Million USD; 2016–2026)HCG Blood testHCG Urine testFSH Urine testApplication Outlook (Revenue in Million USD; 2016–2026)Female fertility testingMale Fertility TestingDistribution Channel Outlook (Revenue in Million USD; 2016–2026)PharmaciesDrugstoresOnline SalesHypermarkets & SupermarketsEnd Use Outlook (Revenue in Million USD; 2016–2026)Home careHospitals, Fertility Clinics,OthersRegional Analysis of the Fertility Testing Devices Market:The report offers a comprehensive regional bifurcation of the key regions included in the Fertility Testing Devices market along with production and consumption patterns, supply and demand ratio, import/export analysis, revenue contribution, market share and size, volume and value, and the operations of the key players located in each key regions.Along with this, the report also offers an estimated year-on-year growth rate of all the regions and their key countries along with total revenue generated by each region during the entirety of the forecast timeline (2020-2027).To know more about the report, visit @ https://www.reportsanddata.com/report-detail/fertility-testing-marketThe regional analysis of the Fertility Testing Devices industry assesses the following crucial geographical regions:North America (U.S., Canada)Europe (U.K., Italy, Germany, France, Rest of EU)Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)Latin America (Chile, Brazil, Argentina, Rest of Latin America)Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)Competitive Landscape:Competitive analysis of the Fertility Testing Devices industry offers key data regarding product portfolio, company overview, market concentration rate, pricing analysis, and other key elements.
2
More

Top